Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

NCT03366324 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
B Cell Lymphoma

Interventions

GENETIC: Second generation CAR-T cells
PROCEDURE: Hematological stem cell transplantation

Sponsor

Wuhan Sian Medical Technology Co., Ltd

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]